(ACRV) Acrivon Therapeutics - Ratings and Ratios
Oncology, Inhibitor, Precision, Platform
| Risk via 10d forecast | |
|---|---|
| Volatility | 99.2% |
| Value at Risk 5%th | 137% |
| Reward | |
|---|---|
| Sharpe Ratio | -0.69 |
| Alpha Jensen | -101.65 |
| Character | |
|---|---|
| Hurst Exponent | 0.206 |
| Beta | 1.837 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.47% |
| Mean DD | 66.35% |
Description: ACRV Acrivon Therapeutics October 19, 2025
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biotech focused on oncology drugs that are paired with proprietary companion diagnostics generated through its AP3 (Acrivon Predictive Precision Proteomics) platform. Its lead asset, ACR-368, is a selective CHK1/CHK2 inhibitor being evaluated in endometrial, platinum-resistant ovarian cancers and squamous cell carcinomas such as SCCHN and anal cancer. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor, and a preclinical cell-cycle program derived from AP3 and co-crystallography data.
Key external data points that may influence ACRV’s valuation: (1) As of the latest 10-Q (Q2 2024), the company reported cash and equivalents of roughly $55 million, giving it ~12-month runway under current burn rates-a critical liquidity metric for early-stage biotechs. (2) The global oncology therapeutics market is projected to grow at a CAGR of ~7 % through 2030, driven by rising cancer incidence and expanding precision-medicine adoption, which underpins demand for biomarker-guided agents like ACR-368. (3) Recent sector trends show heightened investor appetite for companies that integrate companion diagnostics early in development, as FDA guidance increasingly favors co-development pathways that can accelerate regulatory review and market access.
If you want a deeper, data-driven assessment of ACRV’s upside potential, ValueRay’s analytical toolkit offers granular financial and scientific metrics that can help you form a more informed view.
ACRV Stock Overview
| Market Cap in USD | 59m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-11-15 |
| Return 12m vs S&P 500 | -78.2% |
| Analyst Rating | 4.33 of 5 |
ACRV Dividends
Currently no dividends paidACRV Growth Ratios
| CAGR | -50.40% |
| CAGR/Max DD Calmar Ratio | -0.53 |
| CAGR/Mean DD Pain Ratio | -0.76 |
| Current Volume | 297.4k |
| Average Volume | 323.3k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-86.0m TTM) > 0 and > 6% of Revenue (6% = 50.9k TTM) |
| FCFTA -0.46 (>2.0%) and ΔFCFTA -22.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.7k% (prev 9080 %; Δ 5658 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -70.8m > Net Income -86.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.5m) change vs 12m ago 6.45% (target <= -2.0% for YES) |
| Gross Margin -57.43% (prev 52.02%; Δ -109.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.44% (prev 0.82%; Δ -0.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.61 (EBITDA TTM -91.6m / Interest Expense TTM -6.81m) >= 6 (WARN >= 3) |
Altman Z'' -18.96
| (A) 0.79 = (Total Current Assets 138.4m - Total Current Liabilities 13.4m) / Total Assets 158.6m |
| (B) -1.50 = Retained Earnings (Balance) -237.7m / Total Assets 158.6m |
| warn (B) unusual magnitude: -1.50 — check mapping/units |
| (C) -0.48 = EBIT TTM -92.8m / Avg Total Assets 194.6m |
| (D) -15.28 = Book Value of Equity -237.5m / Total Liabilities 15.5m |
| Total Rating: -18.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.99
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield 97.56% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.42 = 2.36 |
| 6. ROIC - WACC (= -55.41)% = -12.50 |
| 7. RoE -50.78% = -2.50 |
| 8. Rev. Trend 11.43% = 0.86 |
| 9. EPS Trend 65.36% = 3.27 |
What is the price of ACRV shares?
Over the past week, the price has changed by -3.72%, over one month by +16.95%, over three months by +68.29% and over the past year by -74.85%.
Is Acrivon Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRV is around 1.50 USD . This means that ACRV is currently overvalued and has a potential downside of -27.54%.
Is ACRV a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACRV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.2 | 439.6% |
| Analysts Target Price | 11.2 | 439.6% |
| ValueRay Target Price | 1.7 | -16.9% |
ACRV Fundamental Data Overview November 11, 2025
P/B = 0.409
Beta = 1.837
Revenue TTM = 848.0k USD
EBIT TTM = -92.8m USD
EBITDA TTM = -91.6m USD
Long Term Debt = 3.26m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 3.26m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -38.6m USD (from netDebt column, last quarter)
Enterprise Value = -75.0m USD (59.1m + Debt 3.26m - CCE 137.4m)
Interest Coverage Ratio = -13.61 (Ebit TTM -92.8m / Interest Expense TTM -6.81m)
FCF Yield = 97.56% (FCF TTM -73.2m / Enterprise Value -75.0m)
FCF Margin = -8631 % (FCF TTM -73.2m / Revenue TTM 848.0k)
Net Margin = -10.1k% (Net Income TTM -86.0m / Revenue TTM 848.0k)
Gross Margin = -57.43% ((Revenue TTM 848.0k - Cost of Revenue TTM 1.33m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.47 (set to none) (Enterprise Value -75.0m / Total Assets 158.6m)
Interest Expense / Debt = 50.17% (Interest Expense 1.64m / Debt 3.26m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.3m (EBIT -92.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.31 (Total Current Assets 138.4m / Total Current Liabilities 13.4m)
Debt / Equity = 0.02 (Debt 3.26m / totalStockholderEquity, last quarter 143.0m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -38.6m / EBITDA -91.6m)
Debt / FCF = 0.53 (negative FCF - burning cash) (Net Debt -38.6m / FCF TTM -73.2m)
Total Stockholder Equity = 169.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.20% (Net Income -86.0m / Total Assets 158.6m)
RoE = -50.78% (Net Income TTM -86.0m / Total Stockholder Equity 169.3m)
RoCE = -53.77% (EBIT -92.8m / Capital Employed (Equity 169.3m + L.T.Debt 3.26m))
RoIC = -43.30% (negative operating profit) (NOPAT -73.3m / Invested Capital 169.3m)
WACC = 12.11% (E(59.1m)/V(62.4m) * Re(12.78%) + (debt cost/tax rate unavailable))
Discount Rate = 12.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.23%
Fair Price DCF = unknown (Cash Flow -73.2m)
EPS Correlation: 65.36 | EPS CAGR: 110.0% | SUE: 4.0 | # QB: 4
Revenue Correlation: 11.43 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for ACRV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle